Like and comment please_老虎社区_美港股上老虎

2021-04-16

Like and comment please

Why Zomedica Stock Plunged Thursday<blockquote>为什么Zomedica股价周四暴跌</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":370036443,"tweetId":"370036443","gmtCreate":1618535271982,"gmtModify":1634292269247,"author":{"id":3574935505074782,"idStr":"3574935505074782","authorId":3574935505074782,"authorIdStr":"3574935505074782","name":"Ailuros","avatar":"https://static.tigerbbs.com/d7896e74e0a34781e49dc0c310e473e2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like and comment please&nbsp;</body></html>","htmlText":"<html><head></head><body>Like and comment please&nbsp;</body></html>","text":"Like and comment please","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/370036443","repostId":1104323307,"repostType":4,"repost":{"id":"1104323307","kind":"news","pubTimestamp":1618534802,"share":"https://www.laohu8.com/m/news/1104323307?lang=zh_CN&edition=full","pubTime":"2021-04-16 09:00","market":"us","language":"en","title":"Why Zomedica Stock Plunged Thursday<blockquote>为什么Zomedica股价周四暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104323307","media":"Motley Fool","summary":"Initial sales of a key product may be lower than investors were hoping for.\nWhat happened\nShares of ","content":"Initial sales of a key product may be lower than investors were hoping for.<blockquote>关键产品的初始销售额可能低于投资者的预期。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Zomedica Pharmaceuticals&nbsp;(NYSEMKT:ZOM)&nbsp;fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy.<blockquote>本公司之股份Zomedica制药公司(NYSEMKT：ZOM)周四下跌13.7%，此前这家兽医保健公司宣布改变销售策略。</blockquote> So what<blockquote>那又怎样</blockquote> Zomedica will build out its internal sales team as it transitions away from its current distributor-based approach. CEO Robert Cohen said the move was precipitated by \"changes at our current distributor that we believe have impacted its ability to market our products effectively.\" Those words likely startled investors, many of whom decided to&nbsp;sell&nbsp;their shares.<blockquote>Zomedica将建立其内部销售团队，摆脱目前基于经销商的方法。首席执行官罗伯特·科恩表示，此举是由于“我们当前经销商的变化，我们认为这些变化影响了其有效营销我们产品的能力。”这些话可能让投资者感到震惊，其中许多人决定出售股票。</blockquote> <img src=\"https://static.tigerbbs.com/2801a170fd507ea28b362a0630d8590b\" tg-width=\"2000\" tg-height=\"1232\">ZOMEDICA'S STOCK PRICE DROPPED SHARPLY ON THURSDAY. IMAGE SOURCE: GETTY IMAGES.<blockquote>ZOMEDICA的股价周四大幅下跌。图片来源：盖蒂图片社。</blockquote> To be fair, Cohen said that while the shift might negatively impact near-term sales of its Truforma diagnostic platform for dogs and cats, it could have some long-term benefits.<blockquote>公平地说，科恩表示，虽然这一转变可能会对其Truforma狗和猫诊断平台的近期销售产生负面影响，但它可能会带来一些长期好处。</blockquote> \"While this effort may slow initial sales of Truforma, we have taken this action now to avoid any disruption to our customers and to provide a stronger foundation on which to build the marketing and sales of both Truforma&nbsp;and any future products developed or acquired by Zomedica,\" Cohen said in a press release.<blockquote>“虽然这一努力可能会减缓Truforma的初始销售，但我们现在采取这一行动是为了避免对我们的客户造成任何干扰，并为Truforma以及Zomedica未来开发或收购的任何产品的营销和销售提供更坚实的基础，”科恩在一份新闻稿中说。</blockquote> Now what<blockquote>现在怎么办</blockquote> Zomedica recorded its first veterinarian sale of Truforma in mid-March. The diagnostic platform lies at the core of the company's commercial strategy and is likely to remain its only revenue generator for some time. Investors, in turn, are understandably concerned about a potential slower sales rollout for Truforma.<blockquote>Zomedica在3月中旬首次记录了Truforma的兽医销售。诊断平台是该公司商业战略的核心，并且可能在一段时间内仍然是其唯一的收入来源。反过来，投资者担心Truforma的销售可能放缓，这是可以理解的。</blockquote> That said, Zomedica raised roughly $200 million via a share offering in February, so it has the cash it needs to ramp up its sales team. Shareholders will need to be patient with Zomedica's new approach, but if Truforma is the game changer management says it is, then sales should eventually materialize.<blockquote>也就是说，Zomedica在2月份通过股票发行筹集了约2亿美元，因此它拥有扩大销售团队所需的现金。股东需要对Zomedica的新方法保持耐心，但如果Truforma像管理层所说的那样改变游戏规则，那么销售最终应该会实现。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Zomedica Stock Plunged Thursday<blockquote>为什么Zomedica股价周四暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Zomedica Stock Plunged Thursday<blockquote>为什么Zomedica股价周四暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-04-16 09:00\n\n</h4>\n</header>\n<article>\nInitial sales of a key product may be lower than investors were hoping for.<blockquote>关键产品的初始销售额可能低于投资者的预期。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Zomedica Pharmaceuticals&nbsp;(NYSEMKT:ZOM)&nbsp;fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy.<blockquote>本公司之股份Zomedica制药公司(NYSEMKT：ZOM)周四下跌13.7%，此前这家兽医保健公司宣布改变销售策略。</blockquote> So what<blockquote>那又怎样</blockquote> Zomedica will build out its internal sales team as it transitions away from its current distributor-based approach. CEO Robert Cohen said the move was precipitated by \"changes at our current distributor that we believe have impacted its ability to market our products effectively.\" Those words likely startled investors, many of whom decided to&nbsp;sell&nbsp;their shares.<blockquote>Zomedica将建立其内部销售团队，摆脱目前基于经销商的方法。首席执行官罗伯特·科恩表示，此举是由于“我们当前经销商的变化，我们认为这些变化影响了其有效营销我们产品的能力。”这些话可能让投资者感到震惊，其中许多人决定出售股票。</blockquote> <img src=\"https://static.tigerbbs.com/2801a170fd507ea28b362a0630d8590b\" tg-width=\"2000\" tg-height=\"1232\">ZOMEDICA'S STOCK PRICE DROPPED SHARPLY ON THURSDAY. IMAGE SOURCE: GETTY IMAGES.<blockquote>ZOMEDICA的股价周四大幅下跌。图片来源：盖蒂图片社。</blockquote> To be fair, Cohen said that while the shift might negatively impact near-term sales of its Truforma diagnostic platform for dogs and cats, it could have some long-term benefits.<blockquote>公平地说，科恩表示，虽然这一转变可能会对其Truforma狗和猫诊断平台的近期销售产生负面影响，但它可能会带来一些长期好处。</blockquote> \"While this effort may slow initial sales of Truforma, we have taken this action now to avoid any disruption to our customers and to provide a stronger foundation on which to build the marketing and sales of both Truforma&nbsp;and any future products developed or acquired by Zomedica,\" Cohen said in a press release.<blockquote>“虽然这一努力可能会减缓Truforma的初始销售，但我们现在采取这一行动是为了避免对我们的客户造成任何干扰，并为Truforma以及Zomedica未来开发或收购的任何产品的营销和销售提供更坚实的基础，”科恩在一份新闻稿中说。</blockquote> Now what<blockquote>现在怎么办</blockquote> Zomedica recorded its first veterinarian sale of Truforma in mid-March. The diagnostic platform lies at the core of the company's commercial strategy and is likely to remain its only revenue generator for some time. Investors, in turn, are understandably concerned about a potential slower sales rollout for Truforma.<blockquote>Zomedica在3月中旬首次记录了Truforma的兽医销售。诊断平台是该公司商业战略的核心，并且可能在一段时间内仍然是其唯一的收入来源。反过来，投资者担心Truforma的销售可能放缓，这是可以理解的。</blockquote> That said, Zomedica raised roughly $200 million via a share offering in February, so it has the cash it needs to ramp up its sales team. Shareholders will need to be patient with Zomedica's new approach, but if Truforma is the game changer management says it is, then sales should eventually materialize.<blockquote>也就是说，Zomedica在2月份通过股票发行筹集了约2亿美元，因此它拥有扩大销售团队所需的现金。股东需要对Zomedica的新方法保持耐心，但如果Truforma像管理层所说的那样改变游戏规则，那么销售最终应该会实现。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/15/why-zomedica-stock-plunged-today/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/15/why-zomedica-stock-plunged-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104323307","content_text":"Initial sales of a key product may be lower than investors were hoping for.\nWhat happened\nShares of Zomedica Pharmaceuticals (NYSEMKT:ZOM) fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy.\nSo what\nZomedica will build out its internal sales team as it transitions away from its current distributor-based approach. CEO Robert Cohen said the move was precipitated by \"changes at our current distributor that we believe have impacted its ability to market our products effectively.\" Those words likely startled investors, many of whom decided to sell their shares.\nZOMEDICA'S STOCK PRICE DROPPED SHARPLY ON THURSDAY. IMAGE SOURCE: GETTY IMAGES.\nTo be fair, Cohen said that while the shift might negatively impact near-term sales of its Truforma diagnostic platform for dogs and cats, it could have some long-term benefits.\n\"While this effort may slow initial sales of Truforma, we have taken this action now to avoid any disruption to our customers and to provide a stronger foundation on which to build the marketing and sales of both Truforma and any future products developed or acquired by Zomedica,\" Cohen said in a press release.\nNow what\nZomedica recorded its first veterinarian sale of Truforma in mid-March. The diagnostic platform lies at the core of the company's commercial strategy and is likely to remain its only revenue generator for some time. Investors, in turn, are understandably concerned about a potential slower sales rollout for Truforma.\nThat said, Zomedica raised roughly $200 million via a share offering in February, so it has the cash it needs to ramp up its sales team. Shareholders will need to be patient with Zomedica's new approach, but if Truforma is the game changer management says it is, then sales should eventually materialize.","news_type":1,"symbols_score_info":{"ZOM":0.9}},"isVote":1,"tweetType":1,"viewCount":344,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/370036443"}